Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23801952 | 0.87 | ALDH1A1 (0.32) | ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL23802011 | 0.82 | GABRA1 (0.35) | ALDH1A1LMNASMN1; SMN2GABRA1GABRB2 | |
| SCHEMBL23801967 | 0.80 | ALDH1A1 (0.30) | ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL19589407 | 0.77 | ALDH1A1 (0.34) | ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL15458994 | 0.75 | ACHE (0.30) | — | |
| SCHEMBL23802251 | 0.75 | ALDH1A1 (0.34) | ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL23801945 | 0.75 | FFAR4 (0.33) | — | |
| SCHEMBL17393750 | 0.74 | GABRA1 (0.46) | ALDH1A1LMNAGABRA1GABRB2 | |
| SCHEMBL962215 | 0.74 | GABRA1 (0.52) | ALDH1A1LMNAGABRA1GABRB2 | |
| SCHEMBL23801948 | 0.72 | RARA (0.32) | ALDH1A1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210284638-A1 | ALPHAvBETA1 INTEGRIN ANTAGONISTS | SAINT LOUIS UNIVERSITY (US) | 2021-09-16 | — | — | US | disclosed |
| US-20210284638-A1 | ALPHAvBETA1 INTEGRIN ANTAGONISTS | SAINT LOUIS UNIVERSITY (US) | 2021-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210284638-A1 | ALPHAvBETA1 INTEGRIN ANTAGONISTS | ITGB1, ITGAV, ITGA1 | ALDH1A1 441/4885LMNA 1799/4885SMN1; SMN2 2205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.